Alkem

{{ Form::open(['url' => '#', 'name' => 'validateForm', 'id' => 'validateForm', 'enctype' => 'multipart/form-data']) }} @csrf

Back

Empire

Assessment of usage of Empagliflozin and combinations in Patients newly diagnosed type 2 diabetes

BASIC DETAILS

Patient code (Do not write name here) *

Date *

Diagnosis : Type 2 diabetes Mellitus (T2DM) {{--

Yes No

--}}

Parameter

Patient's Age (years) *

Gender *

Male Female

HbA1c *

Weight (in Kg) *

Risk factors

Obesity (BMI) *

Underweight (<18.5 kg/m²) Normal BMI (18.5-22.9 kg/m²) Over weight (23.0 -24.9 kg/m²) Obese (>25 kg/m²)

Active Smoker *

Yes No

Alcohol intake *

Yes No

Tobacco use *

Yes No

Family history diabetes *

Yes No

Family history of Heart failure / CKD *

Yes No

Physical inactivity *

Yes No

Clinical examination *

Systolic BP	mmHg
Diastolic BP	mmHg

Comorbid conditions

Preferred FDC of empagliflozin *

Empagliflozin + Linagliptin

10 / 5 mg 25 / 5 mg

Empagliflozin + Metformin

5 / 500 mg 5 / 1000 mg 12.5 / 500 mg 12.5 / 1000 mg Any other

Other antidiabetics and systemic Medications used *

Drug	Dose	Frequency
Glimepiride	1 mg 2 mg	OD BD
Pioglitazone	15 mg 30 mg	OD BD
DPP4 inhibitor Sitagliptin Linagliptin Vildagliptin		OD BD
ARBs/ACE inhibitors ARNI (Sacubitril/valsartan)		OD BD OD BD
Beta blocker Metoprolol Bisoprolol		OD BD
Diuretic		OD BD
Statin and combinations		OD BD
Others		OD BD

Examination & Investigations *

Parameter	Baseline	Observation after 3 months
HbA1C (%)
Fasting Blood Glucose (mg/dl)
Post Prandial Blood Glucose (mg/dl)
Body Weight (Kg)
eGFR

Adverse events seen *

Yes No

Clinician's Global Assessment of safety (Tick Appropriate) *

Excellent Good Fair Poor

Clinician's Global Assessment of Effectiveness (Tick Appropriate) *

Excellent Good Fair Poor

@include('user.footer')

Heart failure	Yes No
Hypertension	Yes No
CKD	Yes No
Stroke	Yes No
MI	Yes No
Any other